[Market Focus] Hanmi Pharmaceutical Surges on Obesity Drug Research Announcing 'Muscle Gain' Effects

Hanmi Pharmaceutical is showing strong performance in early trading on September 23. The surge appears to be driven by buying momentum following the announcement of preclinical research results for its obesity drug candidates.

As of 9:52 a.m. on the Korea Exchange, Hanmi Pharmaceutical's share price was up 6.15% from the previous trading day, reaching 388,500 won. The stock opened at 391,500 won and soared to as high as 396,500 won during the session, hitting a new 52-week high.

From September 15 to 19, Hanmi Pharmaceutical presented six preclinical research findings on three novel obesity drug candidates-including the next-generation triple-action obesity therapy, an oral obesity treatment, and the innovative HM17321-at the 61st European Association for the Study of Diabetes (EASD) held in Vienna, Austria.

Among these, HM17321 is being developed as the world's first innovative obesity drug that not only prevents muscle loss but also simultaneously increases muscle mass and enables selective fat reduction.

This content was produced with the assistance of AI translation services.